Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 2, 2014, Pages 160-166

  Silverberg, Michael J ^a   Leyden, Wendy A ^a   Xu, Lanfang ^b   Horberg, Michael A ^c   Chao, Chun R ^a   Towner, William J ^d   Hurley, Leo B ^a   Quesenberry Jr , Charles P ^a   Klein, Daniel B ^e  

^a DIVISION OF RESEARCH   (United States)

^b Kaiser Permanente South California ^*  (United States)

^c Mid Atlantic Permanente Research Institute   (United States)

^d Section of Infectious Diseases   (United States)

^e Division of Infectious Diseases   (United States)

Author keywords

Epidemiology; HIV AIDS; Immunodeficiency; Myocardial infarction

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTILIPEMIC AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA;

ADULT; ALCOHOL ABUSE; ARTICLE; ASIAN; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABUSE; FEMALE; FOLLOW UP; HEART INFARCTION; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNE DEFICIENCY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEGRO; OBESITY; PACIFIC ISLANDER; POPULATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SOCIAL STATUS; TREATMENT DURATION; UNITED STATES; YOUNG ADULT;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CALIFORNIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; VIRAL LOAD; YOUNG ADULT;

EID: 84893755396     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000009     Document Type: Article

References (44)

1. van Sighem AI, Gras LA, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527-1535.
2. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598.
3. Abrass CK, Appelbaum JS, Boyd CM, et al. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc. 2012;60:974-979.
4. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIVinfected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
5. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-622.
6. Klein D, Hurley LB, Quesenberry CP Jr, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
7. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228-1230.
8. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92: 2506-2512.
9. Eriksson U, Opravil M, Amann FW, et al. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS. 1998;12:2079-2080.
10. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
11. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
12. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
13. Holmberg SD, Moorman AC, Greenberg AE. Trends in rates of myocardial infarction among patients with HIV. N Engl J Med. 2004;350:730-732; author reply 730-732.
14. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360: 1747-1748.
15. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
16. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A: D) study. J Infect Dis. 2010;201:318-330.
17. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis. 2012;205(suppl 3):S368-S374.
18. Towner WJ, Xu L, Leyden WA, et al. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012;60:321-327.
19. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23: 2337-2345.
20. Gordon NP. How Does the Adult Kaiser Permanente Membership in Northern California Compare With the Larger Community?. Available at: http://www.dor.kaiser.org/external/uploadedFiles/content/research/mhs/- 2011-Revised-Site/Documents-Special-Reports/comparison-kaiser-vs- nonKaiser-adults-kpnc(1).pdf. Accessed May 21, 2013.
21. California Department of Health Services, Office of AIDS. HIV/AIDS Surveillance in California. Available at: http://www.cdph.ca.gov/programs/ aids/Documents/SSSemiAnnualRptDec2011.pdf. Accessed May 21, 2013.
22. Elliott MN, Fremont A, Morrison PA, et al. A new method for estimating race/ethnicity and associated disparities where administrative records lack self-reported race/ethnicity. Health Serv Res. 2008;43:1722-1736.
23. Fiscella K, Fremont AM. Use of geocoding and surname analysis to estimate race and ethnicity. Health Serv Res. 2006;41:1482-1500.
24. Derose SF, Contreras R, Coleman KJ, et al. Race and ethnicity data quality and imputation using U.S. Census data in an integrated health system: the Kaiser Permanente Southern California experience. Med Care Res Rev. 2013;70:330-345.
25. Diez-Roux AV, Kiefe CI, Jacobs DR Jr, et al. Area characteristics and individual-level socioeconomic position indicators in three populationbased epidemiologic studies. Ann Epidemiol. 2001;11:395-405.
26. Diez Roux AV, Jacobs DR, Kiefe CI. Neighborhood characteristics and components of the insulin resistance syndrome in young adults: the coronary artery risk development in young adults (CARDIA) study. Diabetes Care. 2002;25:1976-1982.
27. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001; 345:99-106.
28. Diez Roux AV, Merkin SS, Hannan P, et al. Area characteristics, individual-level socioeconomic indicators, and smoking in young adults: the coronary artery disease risk development in young adults study. Am J Epidemiol. 2003;157:315-326.
29. Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 2012;55:600-607.
30. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435-447.
31. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010;55:615-619.
32. Hsue PY, Hunt PW, Ho JE, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail. 2010;3:132-139.
33. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-1608.
34. Ho JE, Scherzer R, Hecht FM, et al. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS. 2012;26: 1115-1120.
35. Landay A, Benning L, Bremer J, et al. Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis. 2003;188:209-218.
36. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13: 177-187.
37. Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23:1743-1753.
38. Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr. 2011;57:245-253.
39. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Ann Intern Med. 2010;170:1228-1238.
40. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11: 130-136.
41. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
42. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441-447.
43. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKlinesponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20-28.
44. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362: 2155-2165.